FDA
-
-
-
-
-
-
-
Clene reports positive ALS biomarker data for CNM-Au8 drug candidate
-
-
-
-
-
-
-
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
-
-
-
-
-
-
-
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
-
-
-
-
-
-
-
Clene (CLNN) and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Clene, Inc. (CLNN)
-
-
-
-
-
-
-
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
-
-
-
-
-
-
-
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

